neuroprotective agents for management of parkinson’s disease
نویسندگان
چکیده
#no abstract#
منابع مشابه
Plant-derived neuroprotective agents in Parkinson's disease.
Parkinson's disease (PD) is one of the most common degenerative disorders of the central nervous system among the elderly. The disease is caused by the slow deterioration of the dopaminergic neurons in the substantia nigra. Treatment strategies to protect dopaminergic neurons from progressive damage have received much attention. However there is no effective treatment for PD. Traditional Chines...
متن کاملglaucomatous optic neuropathy management: the role of neuroprotective agents
glaucoma is a major cause of worldwide irreversible blindness. the central role of raised intraocular pressure (iop) is being questioned as many patients continue to demonstrate a clinically downhill course despite initial control of iop. the latest concept of recognizing glaucoma as a multifactorial, progressive, neurodegenerative disease of retinal ganglion cells (rgcss) associated with chara...
متن کاملNovel anti-inflammatory and neuroprotective agents for Parkinson's disease.
Parkinson's disease (PD) is a type of motor system disorder that results from the progressive loss of dopaminergic (DAergic) neurons in the substantia nigra (SN) of the midbrain. It is one of the most common neurodegenerative disorders, with an incidence that is second only to Alzheimer's disease (AD). Although replacement of dopamine can temporarily alleviate the symptoms of PD patients, it ca...
متن کاملGlaucomatous Optic Neuropathy Management: the Role of Neuroprotective Agents
Glaucoma is a major cause of worldwide irreversible blindness. The central role of raised intraocular pressure (IOP) is being questioned as many patients continue to demonstrate a clinically downhill course despite initial control of IOP. The latest concept of recognizing glaucoma as a multifactorial, progressive, neurodegenerative disease of retinal ganglion cells (RGCSs) associated with chara...
متن کاملErratum: The promise of neuroprotective agents in Parkinson's disease
Received: 27 March 2013; accepted: 15 April 2013; published online: 01 May 2013. Citation: Seidl SE and Potashkin JA (2013) Erratum: The promise of neuroprotective agents in Parkinson’s disease. Front. Neurosci. 7:69. doi: 10.3389/fnins. 2013.00069 This article was submitted to Frontiers in Neuropharmacology, a specialty of Frontiers in Neuroscience. Copyright © 2013 Seidl and Potashkin. This i...
متن کاملThe Promise of Neuroprotective Agents in Parkinson’s Disease
Parkinson's disease (PD) is characterized by loss of dopamine neurons in the substantia nigra of the brain. Since there are limited treatment options for PD, neuroprotective agents are currently being tested as a means to slow disease progression. Agents targeting oxidative stress, mitochondrial dysfunction, and inflammation are prime candidates for neuroprotection. This review identifies Rasag...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
journal of pharmaceutical careجلد ۱، شماره ۱، صفحات ۳۳-۳۷
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023